Remember when Gerald said that the most important thing pharmas care about is "specificity?" With the data we had before in October the specificity was at 90% with sensitivity at 70%. But the 70% number is really irrelevant to pharmas evaluating LymPro; specificity is what they care about and we were already at 90%. ("Highly statistically significant" We're there.

You guys that are spazzing out simply are misunderstanding what is going on. Our numbers are fine for what we are doing. Don't make Gerald make up multivariant numbers prematurely just to please you, when pharma don't really care about that anyway.

My son understands the science of Lympro way better than I do and he was very excited by the presentation. He got out the graphs from the data given before in October and was trying to explain to me the "top line data" in graph form. There is a sliding scale where if you want 90% specificity, you just slide down the graph and see that you get 70% sensitivity. Gerald undoubtedly had graphs on the slides showing this but it didn't translate well verbally.

In my opinion, people pointing out his failure to spit out multivariant spec and sens percentages are missing the point, entirely. I don't think we've missed a step in our quest to sign up pharmas. We'll hear of that soon enough.